نتائج البحث - "Stefanie Srock"

المساهمون: von Minckwitz, Gunter, Puglisi, Fabio, Cortes, Javier, Vrdoljak, Eduard, Marschner, Norbert, Zielinski, Christoph, Villanueva, Cristian, Romieu, Gille, Lang, István, Ciruelos, Eva, DE LAURENTIIS, Michelino, Veyret, Corinne, de Ducla, Sabine, Freudensprung, Ulrich, Srock, Stefanie, Gligorov, Joseph

المصدر: The Lancet Oncology. 15:1269-1278

مصطلحات موضوعية: Oncology, Time Factors, genetic structures, medicine.medical_treatment, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, genetics, skin and connective tissue diseases, Humanized, education.field_of_study, Medicine (all), drug therapy/genetics/mortality/pathology, Remission Induction, Middle Aged, Metastatic breast cancer, Bevacizumab, Treatment Outcome, Local, Retreatment, metastatic breast cancer, Drug, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Combination therapy, Population, Breast Neoplasms, Antibodies, Monoclonal, Humanized, administration /&/ dosage/adverse effects, Antibodies, Disease-Free Survival, Drug Administration Schedule, methods, Dose-Response Relationship, Breast cancer, Internal medicine, medicine, Humans, Neoplasm Invasiveness, education, Survival analysis, Aged, erbB-2, drug therapy/mortality/pathology, Neoplasm Staging, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Patient Selection, Genes, erbB-2, medicine.disease, Survival Analysis, eye diseases, Neoplasm Recurrence, Genes, pathology, sense organs, Neoplasm Recurrence, Local, business, Adult, Aged, Antibodies, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage/adverse effects, Breast Neoplasms, drug therapy/genetics/mortality/pathology, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Follow-Up Studies, Genes, genetics, Humans, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, pathology, Neoplasm Recurrence, drug therapy/mortality/pathology, Neoplasm Staging, Patient Selection, Remission Induction, methods, Retreatment, Survival Analysis, Time Factors, Treatment Outcome, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aba7382055cc3697e1bd7d5369ce2d3
https://doi.org/10.1016/s1470-2045(14)70439-5

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

6

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

المؤلفون: Peter O'Dwyer, J. Tabernero, Ivan Bosanac, Christoph Mancao, A. de Gramont, Dirk Arnold, Stefanie Srock, J. Winter, H.-J. Schmoll, E. Van Cutsem, F. Gilberg, A. Grothey, Michel Ducreux

المصدر: Annals of Oncology. 29:viii714-viii715

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4df8c5d01daf35b367a690268c27572d
https://doi.org/10.1093/annonc/mdy424.020

7

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

المؤلفون: José Bines, Dinesh Doval, Romulo Costa, Sabine de Ducla, Paulo Cortes, Giorgio Mustacchi, Joseph Gligorov, Emilio Alba, Ulrich Freudensprung, Stefanie Srock, Jean-Yves Pierga, Vineet Govinda Gupta

المساهمون: Joseph, Gligorov, Dinesh, Doval, José, Bine, Emilio, Alba, Paulo, Corte, Jean Yves, Pierga, Vineet, Gupta, Rômulo, Costa, Stefanie, Srock, Sabine de, Ducla, Ulrich, Freudensprung, Mustacchi, Giorgio